Concepedia

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

Maja J.A. de Jonge, Marije Slingerland, Walter J. Loos, Erik A.C. Wiemer, Herman Burger, Ron H.J. Mathijssen, Judith R. Kroep, Margret A.G. den Hollander, D. van der Biessen, Mei-Ho Lam,

European Journal of Cancer · 2010 · 90 citations · 13 references

DOI

Concepts

References

13

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Felix E. de Jongh, Ruben N. van Veen, S J Veltman et al. · British Journal of Cancer · 2003 · 265 citations · Full text

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

William C. Zamboni, Anne Gervais, Merrill J. Egorin et al. · Cancer Chemotherapy and Pharmacology · 2004 · 163 citations

, , +9

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

Stuart C. White, Paul Lorigan, Geoffrey P. Margison et al. · British Journal of Cancer · 2006 · 149 citations · Full text

Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study

George P. Stathopoulos, Teni Boulikas, Maria Vougiouka et al. · Oncology Reports · 2005 · 124 citations